3 citations
,
January 2022 in “Journal of Cosmetic Dermatology” Bicalutamide, a drug with a good safety profile, is a promising new treatment for female pattern hair loss.
1 citations
,
March 2022 in “Journal of The American Academy of Dermatology” Adjusting minoxidil dosage may be safer than using bicalutamide for hair loss in women.
5 citations
,
January 2022 in “Drug Delivery” Bimatoprost cream can help regrow hair in baldness.
April 2026 in “Zenodo (CERN European Organization for Nuclear Research)” April 2026 in “Zenodo (CERN European Organization for Nuclear Research)”
3 citations
,
June 2023 in “Journal of cosmetic dermatology” A new drug, abrocitinib, helped a child with severe hair loss regrow hair.
June 2018 in “Disease-a-Month” Remove inflamed cysts surgically, avoid topical antibiotics on wounds, treat skin and mouth conditions with specific medications, and address underlying causes of hair loss.
June 2022 in “Zenodo (CERN European Organization for Nuclear Research)” The hydrogel with neem and tridax extracts effectively treats seborrheic dermatitis.
10 citations
,
June 2018 in “Aaps Pharmscitech” The flutamide-loaded hydrogel is a promising, skin-friendly treatment for acne and hair loss, potentially requiring less frequent application.
3 citations
,
January 2011 in “Indian Journal of Dermatology Venereology and Leprology” Switching to a twice-weekly betamethasone treatment led to full hair regrowth in alopecia areata without side effects.
October 2024 in “The American Journal of Gastroenterology” Upadacitinib improved both Crohn's ileitis and alopecia universalis in a patient.
July 2016 in “Cancer Research” A topical lotion helped manage hair loss from chemotherapy by affecting cell death, inflammation, and collagen, with no side effects.
16 citations
,
March 2016 in “Clinical ophthalmology” Bimatoprost is safe and improves eyelash growth in healthy kids but not in those with eyelash loss from chemotherapy or alopecia.
66 citations
,
December 2018 in “Dermatology” Both ruxolitinib and tofacitinib are effective and safe for treating severe alopecia areata, but relapses are common.
October 2025 in “Indian Dermatology Online Journal” 2.5 mg/ml of triamcinolone acetonide is more effective for treating alopecia areata.
7 citations
,
July 2023 in “Immunotherapy” Ritlecitinib works well and is safe for treating alopecia areata.
May 2025 in “International Journal of Trichology” Topical tofacitinib may help regrow hair in children with alopecia totalis.
July 2018 in “International journal of research - granthaalayah” Croton tiglium application significantly improved hair regrowth in alopecia areata patients.
May 2019 in “Journal of clinical oncology” Topical calcitriol was safe and well-tolerated for potential hair loss prevention in chemotherapy patients.
May 2026 in “Colloids and Surfaces B Biointerfaces” 5 citations
,
May 2024 in “Journal of Allergy and Clinical Immunology Global” Upadacitinib effectively improved severe atopic dermatitis and alopecia universalis in a 29-year-old man.
October 2024 in “International Journal of Research in Dermatology” Tofacitinib is a promising and safe treatment for moderate to severe alopecia areata.
April 2020 in “Trends in Immunotherapy” Combining triamcinolone acetonide and immunotherapy can help regrow hair in some alopecia totalis patients.
February 2026 in “Journal of Cosmetic Dermatology” Combining triamcinolone acetonide with cryotherapy may reduce scalp hair loss more than using triamcinolone alone.
September 2024 in “Indian Journal of Dermatology Venereology and Leprology” Mesotherapy with bicalutamide has limited effectiveness for female hair loss.
3 citations
,
August 2018 in “Journal der Deutschen Dermatologischen Gesellschaft” The technique effectively repairs skin after tumor removal, maintaining appearance and function without complications.
June 2025 in “British Journal of Dermatology” Ritlecitinib may cause serious side effects like blood clots in alopecia areata patients.
March 2025 in “Indian Journal of Dermatology Venereology and Leprology” Tofacitinib is effective for treating alopecia totalis and universalis, with some patients experiencing significant hair regrowth.
August 2020 in “Ugeskrift for Læger” A man with severe hair loss regrew all his hair using tofacitinib and stayed healthy for a year.
August 2025 in “Journal of the American Academy of Dermatology”